- 01865 272 536
Lab Founded in 2015
A/Prof Sparrow awarded an Oxford BHF Centre of Research Excellence Senior Transitional Fellowship in 2015
Dr Ved awarded a Novo Nordisk postdoctoral fellowship in 2016
A/Prof Sparrow awarded a BHF Senior Basic Science Research Fellowship in 2018 and renewed in 2023
A/Prof Sparrow awarded an Additional Ventures project grant in 2021 and extension grant in 2022
Investigating the Genetic and Environmental Causes of Congenital Heart Disease
One out of every 180 babies born in the UK, an average of 12 per day, is diagnosed with an abnormally formed heart - congenital heart disease (CHD). This is the most common type of birth defect, and it is the leading cause of infant death. CHD is more prevalent than most chronic childhood diseases such as autism, cancer or type 1 diabetes, and yet even with the application of the most modern genetic and genomic technologies, the causes of fewer than 1 in 3 cases can be explained genetically. This is partly because our understanding of how the heart forms in the embryo is incomplete, but also because non-genetic factors, such as exposure of the mother or embryo to environmental stresses during pregnancy, can also cause CHD.
I am investigating environmental causes of CHD, using genetically-modified mouse models in a project funded by the British Heart Foundation. Environmental risk factors that significantly increase the incidence of CHD in humans include smoking, viral infection and fever (e.g. Rubella virus), medications taken during pregnancy (e.g. anti-epilepsy or anti-heart arrhythmia drugs), or maternal illnesses (e.g. pre-gestational diabetes). I am investigating how such environmental conditions perturb the process of heart formation in the embryo at both cellular and molecular levels. The potential benefits of my research will be to allow formulation of better advice to women planning pregnancy about what the high risk environmental factors are, and how to minimize exposure to them. Ultimately my results could be used to design and test therapies to reduce the incidence of environmentally-caused CHD, following the folic acid/neural tube defects paradigm.